This Article Full Text Full Text (PDF) Other Versions of this Article: JVI.02524-06v1 81/11/5829    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Robida, J. M. Articles by Tang, H. Search for Related Content PubMed PubMed Citation Articles by Robida, J. M. Articles by Tang, H.

Characterization of Hepatitis C Virus Subgenomic Replicon Resistance to Cyclosporine In Vitro

John M. Robida, Heather B. Nelson, Zhe Liu, and Hengli Tang^*

Department of Biological Science, Florida State University, Tallahassee, Florida 32306-4370

Received 15 November 2006/ Accepted 11 March 2007

Treatment of hepatitis C virus (HCV) infection has been met with less than satisfactory results due primarily to its resistance to and significant side effects from alpha interferon (IFN-). New classes of safe and broadly acting treatments are urgently needed. Cyclosporine (CsA), an immunosuppressive and anti-inflammatory drug for organ transplant patients, has recently been shown to be highly effective in suppressing HCV replication through a mechanism that is distinct from the IFN pathway. Here we report the selection and characterization of HCV replicon cells that are resistant to CsA treatment in vitro, taking advantage of our ability to sort live cells that are actively replicating HCV RNA in the presence of drug treatments. This resistance is specific to CsA as the replicon cells most resistant to CsA were still sensitive to IFN- and a polymerase inhibitor. We demonstrate that the resistant phenotype is not a result of general enhanced replication and, furthermore, that mutations in the coding region of HCV NS5B contribute to the resistance. Interestingly, a point mutation (I432V) isolated from the most resistant replicon was able to rescue a lethal mutation (P540A) in NS5B that disrupts its interaction with its cofactor, cyclophilin B (CypB), even though the I432V mutation is located outside of the reported CypB binding site (amino acids 520 to 591). Our results demonstrate that CsA exerts selective pressure on the HCV genome, leading to the emergence of resistance-conferring mutations in the viral genome despite acting upon a cellular protein.

Published ahead of print on 21 March 2007.

These authors contributed equally to this work.

This article has been cited by other articles:

• Chinnaswamy, S., Yarbrough, I., Palaninathan, S., Kumar, C. T. R., Vijayaraghavan, V., Demeler, B., Lemon, S. M., Sacchettini, J. C., Kao, C. C. (2008). A Locking Mechanism Regulates RNA Synthesis and Host Protein Interaction by the Hepatitis C Virus Polymerase. J. Biol. Chem. 283: 20535-20546 [Abstract] [Full Text]  
• Yang, F., Robotham, J. M., Nelson, H. B., Irsigler, A., Kenworthy, R., Tang, H. (2008). Cyclophilin A Is an Essential Cofactor for Hepatitis C Virus Infection and the Principal Mediator of Cyclosporine Resistance In Vitro. J. Virol. 82: 5269-5278 [Abstract] [Full Text]  
• Okamoto, T., Omori, H., Kaname, Y., Abe, T., Nishimura, Y., Suzuki, T., Miyamura, T., Yoshimori, T., Moriishi, K., Matsuura, Y. (2008). A Single-Amino-Acid Mutation in Hepatitis C Virus NS5A Disrupting FKBP8 Interaction Impairs Viral Replication. J. Virol. 82: 3480-3489 [Abstract] [Full Text]